Therapies database

Find a therapy. Follow the evidence.

See what is being studies, who is developing it, and how far it has progressed.

Search therapy records

Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.

More filters and sort (1 active)

Company-led only

6 results

Therapy	Approach	Progress	Population	Additional Info
SENS-401 (Arazasetron) by SensorionSensorion Compare	Small Molecule	Stage: Phase 2Status: Active	Adults · ≥18 yearsSSNHL, cisplatin, or cochlear-implant cohorts
AC102 by AudioCure PharmaAudioCure Pharma Compare	Small Molecule	Stage: Phase 2Status: Active	Adults · 18–85 yearsRecent severe unilateral ISSNHL
NS101 by Neuracle ScienceNeuracle Science Co., Ltd. Compare	Biologic	Stage: Phase 1/2Status: Active	Adults · 19–70 yearsSteroid-treated persistent unilateral SSNHL
FX-322 by Frequency TherapeuticsFrequency Therapeutics Compare	Regenerative Medicine	Stage: Phase 2Status: Discontinued	Adults · 18–65 yearsStable noise- or sudden-onset SNHL
AM-111 by Auris Medical and AltamiraAltamira Therapeutics Compare	Biologic	Stage: Phase 3Status: Discontinued	Adults · ≥18 yearsSevere acute unilateral SSNHL
Strekin STR001 for Sudden Sensorineural Hearing LossStrekin AG Compare	Small Molecule	Stage: Phase 3Status: Completed	Adults · ≥18 yearsAcute idiopathic or noise-trauma SSNHL

SENS-401 (Arazasetron) by Sensorion

Sensorion · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Population

Adults · ≥18 years

SSNHL, cisplatin, or cochlear-implant cohorts

Evidence

company

Confidence

94%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCisplatin-Induced Hearing Loss

AC102 by AudioCure Pharma

AudioCure Pharma · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Population

Adults · 18–85 years

Recent severe unilateral ISSNHL

Evidence

trial

Confidence

91%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossTinnitus

NS101 by Neuracle Science

Neuracle Science Co., Ltd. · Biologic · Phase 1/2

ActiveTherapeuticStronger sources

Population

Adults · 19–70 years

Steroid-treated persistent unilateral SSNHL

Evidence

trial

Confidence

92%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCochlear Synaptopathy

FX-322 by Frequency Therapeutics

Frequency Therapeutics · Regenerative Medicine · Phase 2

DiscontinuedTherapeutic

Population

Adults · 18–65 years

Stable noise- or sudden-onset SNHL

Evidence

company

Confidence

96%

Indications

Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossSudden Sensorineural Hearing Loss

AM-111 by Auris Medical and Altamira

Altamira Therapeutics · Biologic · Phase 3

DiscontinuedTherapeutic

Population

Adults · ≥18 years

Severe acute unilateral SSNHL

Evidence

company

Confidence

95%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing Loss

Strekin STR001 for Sudden Sensorineural Hearing Loss

Strekin AG · Small Molecule · Phase 3

CompletedTherapeutic

Population

Adults · ≥18 years

Acute idiopathic or noise-trauma SSNHL

Evidence

registry

Confidence

82%

Indications

Hearing LossSudden Sensorineural Hearing LossSensorineural Hearing Loss

A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.

How records are checked